Literature DB >> 21525000

Phospholipase D regulates myogenic differentiation through the activation of both mTORC1 and mTORC2 complexes.

Rami Jaafar1, Caroline Zeiller, Luciano Pirola, Antonio Di Grazia, Fabio Naro, Hubert Vidal, Etienne Lefai, Georges Némoz.   

Abstract

How phospholipase D (PLD) is involved in myogenesis remains unclear. At the onset of myogenic differentiation of L6 cells induced by the PLD agonist vasopressin in the absence of serum, mTORC1 complex was rapidly activated, as reflected by phosphorylation of S6 kinase1 (S6K1). Both the long (p85) and short (p70) S6K1 isoforms were phosphorylated in a PLD1-dependent way. Short rapamycin treatment specifically inhibiting mTORC1 suppressed p70 but not p85 phosphorylation, suggesting that p85 might be directly activated by phosphatidic acid. Vasopressin stimulation also induced phosphorylation of Akt on Ser-473 through PLD1-dependent activation of mTORC2 complex. In this model of myogenesis, mTORC2 had a positive role mostly unrelated to Akt activation, whereas mTORC1 had a negative role, associated with S6K1-induced Rictor phosphorylation. The PLD requirement for differentiation can thus be attributed to its ability to trigger via mTORC2 activation the phosphorylation of an effector that could be PKCα. Moreover, PLD is involved in a counter-regulation loop expected to limit the response. This study thus brings new insights in the intricate way PLD and mTOR cooperate to control myogenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21525000      PMCID: PMC3121405          DOI: 10.1074/jbc.M110.203885

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  62 in total

1.  Syndecan-4 regulates subcellular localization of mTOR Complex2 and Akt activation in a PKCalpha-dependent manner in endothelial cells.

Authors:  Chohreh Partovian; Rong Ju; Zhen W Zhuang; Kathleen A Martin; Michael Simons
Journal:  Mol Cell       Date:  2008-10-10       Impact factor: 17.970

2.  Phospholipase D2-derived phosphatidic acid binds to and activates ribosomal p70 S6 kinase independently of mTOR.

Authors:  Nicholas Lehman; Bill Ledford; Mauricio Di Fulvio; Kathleen Frondorf; Linda C McPhail; Julian Gomez-Cambronero
Journal:  FASEB J       Date:  2007-01-22       Impact factor: 5.191

3.  Optimization of halopemide for phospholipase D2 inhibition.

Authors:  Lauren Monovich; Benjamin Mugrage; Elizabeth Quadros; Karen Toscano; Ruben Tommasi; Stacey LaVoie; Eugene Liu; Zhengming Du; Daniel LaSala; William Boyar; Paul Steed
Journal:  Bioorg Med Chem Lett       Date:  2007-01-25       Impact factor: 2.823

4.  Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling.

Authors:  Tsuneo Ikenoue; Ken Inoki; Qian Yang; Xiaoming Zhou; Kun-Liang Guan
Journal:  EMBO J       Date:  2008-06-19       Impact factor: 11.598

Review 5.  mTOR signaling: PLD takes center stage.

Authors:  Yuting Sun; Jie Chen
Journal:  Cell Cycle       Date:  2008-10-27       Impact factor: 4.534

6.  Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1.

Authors:  Margit Rosner; Markus Hengstschläger
Journal:  Hum Mol Genet       Date:  2008-07-08       Impact factor: 6.150

7.  Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.

Authors:  Sarah A Scott; Paige E Selvy; Jason R Buck; Hyekyung P Cho; Tracy L Criswell; Ashley L Thomas; Michelle D Armstrong; Carlos L Arteaga; Craig W Lindsley; H Alex Brown
Journal:  Nat Chem Biol       Date:  2009-01-11       Impact factor: 15.040

8.  PLD regulates myoblast differentiation through the mTOR-IGF2 pathway.

Authors:  Mee-Sup Yoon; Jie Chen
Journal:  J Cell Sci       Date:  2008-01-15       Impact factor: 5.285

9.  Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR.

Authors:  V Veverka; T Crabbe; I Bird; G Lennie; F W Muskett; R J Taylor; M D Carr
Journal:  Oncogene       Date:  2007-08-06       Impact factor: 9.867

10.  5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis.

Authors:  Wenjuan Su; Oladapo Yeku; Srinivas Olepu; Alyssa Genna; Jae-Sook Park; Hongmei Ren; Guangwei Du; Michael H Gelb; Andrew J Morris; Michael A Frohman
Journal:  Mol Pharmacol       Date:  2008-12-08       Impact factor: 4.436

View more
  17 in total

Review 1.  Rapamycin passes the torch: a new generation of mTOR inhibitors.

Authors:  Don Benjamin; Marco Colombi; Christoph Moroni; Michael N Hall
Journal:  Nat Rev Drug Discov       Date:  2011-10-31       Impact factor: 84.694

2.  An In Vitro TORC1 Kinase Assay That Recapitulates the Gtr-Independent Glutamine-Responsive TORC1 Activation Mechanism on Yeast Vacuoles.

Authors:  Mirai Tanigawa; Tatsuya Maeda
Journal:  Mol Cell Biol       Date:  2017-06-29       Impact factor: 4.272

3.  Role of the mTORC1 complex in satellite cell activation by RNA-induced mitochondrial restoration: dual control of cyclin D1 through microRNAs.

Authors:  Sukanta Jash; Gunjan Dhar; Utpalendu Ghosh; Samit Adhya
Journal:  Mol Cell Biol       Date:  2014-07-21       Impact factor: 4.272

4.  Raptor and Rheb negatively regulate skeletal myogenesis through suppression of insulin receptor substrate 1 (IRS1).

Authors:  Yejing Ge; Mee-Sup Yoon; Jie Chen
Journal:  J Biol Chem       Date:  2011-08-18       Impact factor: 5.157

5.  LACTB is a tumour suppressor that modulates lipid metabolism and cell state.

Authors:  Zuzana Keckesova; Joana Liu Donaher; Jasmine De Cock; Elizaveta Freinkman; Susanne Lingrell; Daniel A Bachovchin; Brian Bierie; Verena Tischler; Aurelia Noske; Marian C Okondo; Ferenc Reinhardt; Prathapan Thiru; Todd R Golub; Jean E Vance; Robert A Weinberg
Journal:  Nature       Date:  2017-03-22       Impact factor: 49.962

6.  Phospholipase D in TCR-Mediated Signaling and T Cell Activation.

Authors:  Minghua Zhu; Daniel P Foreman; Sarah A O'Brien; Yuefei Jin; Weiguo Zhang
Journal:  J Immunol       Date:  2018-01-31       Impact factor: 5.422

Review 7.  Mammalian target of rapamycin (mTOR) signaling network in skeletal myogenesis.

Authors:  Yejing Ge; Jie Chen
Journal:  J Biol Chem       Date:  2012-10-31       Impact factor: 5.157

8.  IKK-β mediates hydrogen peroxide induced cell death through p85 S6K1.

Authors:  C-H Jia; M Li; J Liu; L Zhao; J Lin; P-L Lai; X Zhou; Y Zhang; Z-G Chen; H-Y Li; A-L Liu; C-L Yang; T-M Gao; Y Jiang; X-C Bai
Journal:  Cell Death Differ       Date:  2012-09-07       Impact factor: 15.828

9.  TNF-α- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism.

Authors:  Joffrey De Larichaudy; Alessandra Zufferli; Filippo Serra; Andrea M Isidori; Fabio Naro; Kevin Dessalle; Marine Desgeorges; Monique Piraud; David Cheillan; Hubert Vidal; Etienne Lefai; Georges Némoz
Journal:  Skelet Muscle       Date:  2012-01-18       Impact factor: 4.912

10.  Mitochondrial ROS-derived PTEN oxidation activates PI3K pathway for mTOR-induced myogenic autophagy.

Authors:  Jin-Hwan Kim; Tae Gyu Choi; Seolhui Park; Hyeong Rok Yun; Ngoc Ngo Yen Nguyen; Yong Hwa Jo; Miran Jang; Jieun Kim; Joungmok Kim; Insug Kang; Joohun Ha; Michael P Murphy; Dean G Tang; Sung Soo Kim
Journal:  Cell Death Differ       Date:  2018-07-24       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.